Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Ponte Vedra, FL, United States. The current CEO is Quang X. Pham.
CVKD has IPO date of 2023-01-20, 4 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $12.01M.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
